PMID- 16633143
OWN - NLM
STAT- MEDLINE
DCOM- 20070404
LR  - 20181201
IS  - 0271-0749 (Print)
IS  - 0271-0749 (Linking)
VI  - 26
IP  - 2
DP  - 2006 Apr
TI  - Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related 
      posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial.
PG  - 152-6
AB  - BACKGROUND: Motor vehicle accidents (MVAs) are a leading cause of posttraumatic 
      stress disorder (PTSD) in the general population. Alterations in norepinephrine 
      and serotonin systems have been proposed as mechanisms involved in the 
      pathophysiology of the condition, with treatment directed at these 
      neurotransmitter systems. Reboxetine, a selective norepinephrine reuptake 
      inhibitor, exhibits high affinity and selectivity for the human norepinephrine 
      transporter. Inasmuch as PTSD may be associated with dysregulation of 
      noradrenergic activity, the present double-blind randomized clinical trial 
      intended to evaluate reboxetine's efficacy in the management of MVA-related PTSD 
      and to compare its efficacy with a medication commonly used in PTSD, the 
      selective serotonin reuptake inhibitor fluvoxamine. METHODS: Forty patients with 
      MVA-related PTSD attending a local community mental health outpatient clinic were 
      randomized to receive a fixed dose of either reboxetine (8 mg/d) or fluvoxamine 
      (150 mg/d) in a double-blind fashion for a period of 8 weeks. RESULTS: At 
      baseline and at study end point, the 2 subgroups demonstrated no statistical 
      differences in scores on PTSD, depression, and anxiety rating scales. Both 
      medications led to significant improvements in all clinical scales measured. Nine 
      patients receiving reboxetine and 3 receiving fluvoxamine withdrew from the study 
      because of side effects. CONCLUSIONS: Study observations indicate comparable 
      efficacy of reboxetine and fluvoxamine in the management of MVA-related PTSD 
      despite reboxetine's selective noradrenergic activity. Reboxetine appears to be 
      at least as effective as fluvoxamine and may offer an alternative management 
      option in this often difficult-to-treat and disabling condition. A lower and 
      flexible reboxetine dosing schedule will be recommended for future research to 
      improve its tolerability in PTSD patients.
FAU - Spivak, Baruch
AU  - Spivak B
AD  - Ness-Ziona Mental Health Center, Ness-Ziona, Israel. spivakb@post.tau.ac.il
FAU - Strous, Rael D
AU  - Strous RD
FAU - Shaked, Ginette
AU  - Shaked G
FAU - Shabash, Evgeny
AU  - Shabash E
FAU - Kotler, Moshe
AU  - Kotler M
FAU - Weizman, Abraham
AU  - Weizman A
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Psychopharmacol
JT  - Journal of clinical psychopharmacology
JID - 8109496
RN  - 0 (Antidepressive Agents, Second-Generation)
RN  - 0 (Antidepressive Agents, Tricyclic)
RN  - 0 (Morpholines)
RN  - 947S0YZ36I (Reboxetine)
RN  - O4L1XPO44W (Fluvoxamine)
SB  - IM
MH  - *Accidents, Traffic
MH  - Adult
MH  - Ambulatory Care Facilities
MH  - Antidepressive Agents, Second-Generation/adverse effects/*therapeutic use
MH  - Antidepressive Agents, Tricyclic/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Fluvoxamine/adverse effects/*therapeutic use
MH  - Humans
MH  - Israel
MH  - Male
MH  - Morpholines/adverse effects/*therapeutic use
MH  - Psychiatric Status Rating Scales
MH  - Reboxetine
MH  - Stress Disorders, Post-Traumatic/*drug therapy
MH  - Treatment Outcome
EDAT- 2006/04/25 09:00
MHDA- 2007/04/05 09:00
CRDT- 2006/04/25 09:00
PHST- 2006/04/25 09:00 [pubmed]
PHST- 2007/04/05 09:00 [medline]
PHST- 2006/04/25 09:00 [entrez]
AID - 00004714-200604000-00007 [pii]
AID - 10.1097/01.jcp.0000203195.65710.f0 [doi]
PST - ppublish
SO  - J Clin Psychopharmacol. 2006 Apr;26(2):152-6. doi: 
      10.1097/01.jcp.0000203195.65710.f0.